RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR AFTER KIDNEY TRANSPLANTATION

Abstract

rhG-CSF was safe and effective in leukopenic kidney graft recipients. Leukopenic episodes in treated patients were significantly shorter, and infections occurred at a significantly lower rate. No evidence was found that rhG-CSF therapy might trigger rejection episodes, and no side effects were observed.